Nong Xu
About
Nong Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Nong Xu has authored 96 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 18 papers in Surgery. Recurrent topics in Nong Xu's work include Cancer Immunotherapy and Biomarkers (30 papers), Gastric Cancer Management and Outcomes (27 papers) and Colorectal Cancer Treatments and Studies (18 papers). Nong Xu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (30 papers), Gastric Cancer Management and Outcomes (27 papers) and Colorectal Cancer Treatments and Studies (18 papers). Nong Xu collaborates with scholars based in China, United States and Canada. Nong Xu's co-authors include Yuxian Bai, Jianming Xu, Shukui Qin, Ying Cheng, Jianping Xiong, Liwei Wang, Weijian Guo, Zhehai Wang, Guoping Sun and Leizhen Zheng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and ACS Nano.
In The Last Decade
Nong Xu
93 papers receiving 1.6k citations
Hit Papers
Peers
Nong Xu
Autumn J. McRee United States
Roberto Pazo-Cid Spain
Heung-Moon Chang South Korea
Seiji Igarashi Japan
Yoshitaka Honma Japan
Simona Gurzu Romania
H. J. Wanebo United States
Shozo Yokoyama Japan
Léonor Benhaïm France
Caroline S. Verbeke United Kingdom
Citations per year, relative to Nong Xu Nong Xu (= 1×)
peers
Autumn J. McRee
Countries citing papers authored by Nong Xu
Since
Specialization
Citations
This map shows the geographic impact of Nong Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nong Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nong Xu more than expected).
Fields of papers citing papers by Nong Xu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nong Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nong Xu. The network helps show where Nong Xu may publish in the future.
Co-authorship network of co-authors of Nong Xu
This figure shows the co-authorship network connecting the top 25 collaborators of Nong Xu. A scholar is included among the top collaborators of Nong Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nong Xu. Nong Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yin, Kun, Nong Xu, Yi-Ming Zhang, et al.. (2025). Adaptive Surfaces with Stimuli-Responsive Wettability: From Tailoring to Applications. ACS Nano. 19(7). 6729–6747.
2.
Liu, Furong, Xichun Hu, Jian Zhang, et al.. (2024). The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study. Journal of Hematology & Oncology. 17(1). 118–118.
3.
Ma, Fei, Jingfen Wang, Herui Yao, et al.. (2024). Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1110–1110.
4.
Chen, Yiran, Junjie Jiang, Xiaolu Ma, et al.. (2024). New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges. Briefings in Bioinformatics. 25(2).
5.
Zhou, Jian‐Liang, et al.. (2024). The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification. Cancer Cell International. 24(1). 120–120.
6.
Mao, Chenyu, Yuan Gao, Ying Liu, et al.. (2023). Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study.. Journal of Clinical Oncology. 41(16_suppl). 2576–2576.
7.
Ma, Fei, et al.. (2023). A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 3029–3029.
8.
Ma, Jun, Huiqiang Huang, Peifen Fu, et al.. (2021). Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Annals of Translational Medicine. 9(10). 893–893.
9.
Xu, Jianming, Yuxian Bai, Nong Xu, et al.. (2020). Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 26(17). 4542–4550.
10.
Zhou, Zhong-Hai, Jin Xu, Lizong Shen, et al.. (2020). 1165P Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep). Annals of Oncology. 31. S775–S775.
11.
Xu, Jingyuan, Lin Shen, Chunmei Bai, et al.. (2020). 1156O Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821). Annals of Oncology. 31. S770–S770.
12.
Shen, Lin, J. Li, Nong Xu, et al.. (2020). 1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study. Annals of Oncology. 31. S909–S909.
13.
Wang, Feng‐Hua, Xiaoli Wei, J. Feng, et al.. (2019). Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.. Journal of Clinical Oncology. 37(15_suppl). 6017–6017.
14.
Ying, Kejing, et al.. (2018). OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 13(12). S1047–S1047.
15.
Lü, Zhihao, Xiaotian Zhang, Wei Liu, et al.. (2018). A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 21(5). 782–791.
16.
Gong, Jifang, Tianshu Liu, Qingxia Fan, et al.. (2016). Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 16(1). 68–68.
17.
Zheng, Yulong, et al.. (2015). Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review. Oncology Letters. 9(5). 2041–2045.
18.
Huang, Dingzhi, Yi Ba, Jianping Xiong, et al.. (2013). A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer. European Journal of Cancer. 49(14). 2995–3002.
19.
Dong, Mei, Feng-yi Feng, Yang Zhang, et al.. (2008). [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].. PubMed. 30(3). 215–20.
20.
Xu, Nong, et al.. (2007). A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium. BMC Cancer. 7(1). 98–98.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Autumn J. McRee Breakdown of academic impact, for papers by Roberto Pazo-Cid Breakdown of academic impact, for papers by Heung-Moon Chang Breakdown of academic impact, for papers by Seiji Igarashi Breakdown of academic impact, for papers by Yoshitaka Honma Breakdown of academic impact, for papers by Simona Gurzu Breakdown of academic impact, for papers by H. J. Wanebo Breakdown of academic impact, for papers by Shozo Yokoyama Breakdown of academic impact, for papers by Léonor Benhaïm Breakdown of academic impact, for papers by Caroline S. Verbeke